Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study

A triple negative breast cancer model using the murine 4T1 tumor cell line was used to explore the efficacy of an adjuvanted survivin peptide microparticle vaccine using tumor growth as the outcome metric. We first performed tumor cell dose titration studies to determine a tumor cell dose that resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Burkholz, Scott R., Herst, Charles V., Carback, Richard T., Harris, Paul E., Rubsamen, Reid M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051918/
https://www.ncbi.nlm.nih.gov/pubmed/36992227
http://dx.doi.org/10.3390/vaccines11030644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051918/
https://www.ncbi.nlm.nih.gov/pubmed/36992227
http://dx.doi.org/10.3390/vaccines11030644

Ejemplares similares